Skip to main content
Aller à la page d’accueil de la Commission européenne (s’ouvre dans une nouvelle fenêtre)
français fr
CORDIS - Résultats de la recherche de l’UE
CORDIS

Cellular Sentries for the Interception of Colorectal Tumorigenesis in Lynch Syndrome

Objectif

Our understanding of how the immune system shapes human tumorigenesis comes mainly from invasive cancers that have escaped immune control. Mice cannot fully reproduce this process, leaving the earliest phases of human immunosurveillance unresolved. To address this gap, I established systemic biosampling across tumorigenesis in patients with Lynch syndrome (LS), a hereditary cancer predisposition and unique model for immunosurveillance. During their lifespans, LS patients accumulate immunogenic mismatch repair-deficient (MMRd) progenitor lesions leading to invasive cancers frequently missed by screening due to their unusually rapid outgrowth. My central hypothesis is this rapid cancer onset is enabled by early systemic immune dysfunction resulting from chronic antigen exposure. To resolve this, CENTRI will define when systemic immunosurveillance emerges and fails in LS and how this collapse relates to tissue-level escape thereby identifying windows for optimal cancer interception.
CENTRI pursues three objectives to realize this aim: First (SO1), we will develop a computational framework to reconstruct the onset and evolution of systemic immunosurveillance from blood single-cell data. This will be augmented by a new in-patient antigen perturbation assay which will allow us for the first time to phenotypically characterise neoantigen-specific T cells in cancer-free patients. Second (SO2), we will define the co-evolution of systemic and tissue-level immune escape by mapping neoantigen-reactive T cells and Natural Killer (NK) cells from blood to colorectal cancer precursors. Third (SO3), we will functionally test T and NK cell surveillance across tumorigenesis stages using avatar mice engrafted with patient-derived immune cells and MMRd colorectal cancers. Together, CENTRI promises to delineate the emergence and failure of human immunosurveillance, advance our quantitative understanding of systemic immunity, and provide the basis for immune-based cancer interception.

Champ scientifique (EuroSciVoc)

Ce projet n'a pas encore été classé par EuroSciVoc.
Proposez les domaines scientifiques qui vous semblent les plus pertinents et aidez-nous à améliorer notre service de classification.

Mots‑clés

Programme(s)

Thème(s)

Régime de financement

HORIZON-ERC - HORIZON ERC Grants

Voir tous les projets financés dans le cadre de ce programme de financement

Appel à propositions

(s’ouvre dans une nouvelle fenêtre) ERC-2026-STG

Voir tous les projets financés au titre de cet appel

Institution d’accueil

FUNDACIO DE RECERCA CLINIC BARCELONA-INSTITUT D INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
Contribution nette de l'UE
€ 1 784 143,00
Coût total
€ 1 797 893,00

Bénéficiaires (2)